BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:29 PM
 | 
Oct 01, 2012
 |  BC Extra  |  Company News

Europe approves Seebri

The European Commission approved Seebri Breezhaler glycopyrronium bromide ( NVA237) from Novartis AG (NYSE:NVS; SIX:NOVN) as a once-daily, inhaled maintenance bronchodilator therapy...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >